Monoclonal antibodies that block PD-1/PD-L1 interactions, known as immune checkpoint inhibitors (ICIs), reinvigorate the cancer-killing activity of T-cells, leading to improved tumor immune surveillance. This evidence concerns the gene CD274 and neoplasm.